Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10212477 | Multiple Sclerosis and Related Disorders | 2018 | 10 Pages |
Abstract
Natalizumab is a monoclonal antibody licensed for the treatment of relapsing-remitting multiple sclerosis (RRMS). It is known to increase the potential risk of developing progressive multifocal leukoencephalopathy (PML). There is current debate in the literature regarding its association with malignant melanoma. Herein, we report a case of a 55-year old lady with RRMS for whom natalizumab therapy was being considered by her neurologist. Her medical history included a choroidal melanoma which had undergone successful treatment. Additionally, in this case study we discuss the issues regarding malignant melanoma risk and recurrence with natalizumab treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Abigail E. Kaye, Elizabeth D. Hawkes, Irina I. Gout, Ahmed N. El-Amir, James E. Neffendorf,